Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 60 results for hypoglycaemia

  1. Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]

    Topic prioritisation

  2. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  3. Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

    This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.

  4. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

  5. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  6. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  7. Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

  8. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  9. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  10. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

  11. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  12. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)

    Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.

  13. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

  14. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

  15. Intravenous fluid therapy in children and young people in hospital (NG29)

    This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.